AMLo Biosciences

AMLo Biosciences develops prognostic and companion diagnostic tests for cancers, specifically focusing on melanoma, cutaneous squamous cell carcinoma, and oropharyngeal squamous cell carcinoma. Its primary product, AMBLor, is a prognostic test designed to identify a patient's risk of disease progression to enable risk stratification and personalized follow-up care. The company targets clinicians and global healthcare economies to improve patient outcomes and reduce the financial burden of skin cancer treatment.